Case File
efta-efta01770826DOJ Data Set 10CorrespondenceEFTA Document EFTA01770826
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01770826
Pages
0
Persons
0
Integrity
No Hash Available
Loading PDF viewer...
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Barrett, Paul S
Sent:
Monday, February 13, 2012 4:02 PM
To:
Jeffrey epstein
Subject:
RE: SP500 Notes
Tried calling. When will you be free?
Paul Barrett, CFA
Managing Director
Global Investment Opportunities Group
From: jeffrey epstein Imailto:[email protected]
Sent: Friday, February 10, 2012 3:32 PM
To: Barrett, Paul S
Subject: Re: SP500 Notes
Talk to monday
Sorry for all the typos .Sent from my iPhone
On Feb 10, 2012, at 4:00 PM, "Barrett, Paul S"
wrote:
Hi Jeffrey
We have 2 S&P500 notes.
$5mm of a note expiring 20Jun12 with a buffer from 1256 down to 930. This pays the greater of the upside or a
0% coupon.
-
$2mm of a note expiring 07Feb13 with a buffer from 1260 down to 945. This pays the greater of the upside or a
6.25% coupon.
I think we should consider unwinding the $5MM structure, locking in the profits and resetting into a new note with
either:
A. 15 month market plus that pays the greater of 0% or the upside of the stock with a 75% (so protected from 1340
down 1005) buffer with daily barrier observations OR
EFTA_R1_00082111
EFTA01770826
B.
A dual directional note that has upside exposure between 1340 and 1535 and upside exposure from 1340 down to
1072 (so if the market is down 15% from here, you make 15%). If 1072 trades in the next 12 months you are long at 1340
and would be down 20%.
C.
Optimal entry note which gives you 2x leverage capped at 6.5% but your starting point is the lowest closing point of
the S&P over the next 2 months. 15 months maturity.
Paul
Paul Barrett, CFA
Managing Director
Global Investment Opportunities Group
!Mar an Private Bank
This email is confidential and subject to important disclaimers and conditions including on offers for the purchase or sale
of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege, and legal entity
disclaimers, available at http://www.jpmorgan.com/pages/disclosures/email.
2
EFTA_R1_00082112
EFTA01770827
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]URL
http://www.jpmorgan.com/pages/disclosures/emailRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.